West Asia Conflict Impacts Pharma, But Medicine Prices Won't Rise Yet

The conflict in West Asia is disrupting petrochemical supply chains, increasing raw material costs for the pharmaceutical industry. Jatish Sheth of Srushti Pharmaceuticals states that while input costs have risen, medicine prices cannot be increased without government permission. In response, the Indian government has announced a full customs duty exemption on critical petrochemical products until June 2026 to cushion domestic industries. This exemption aims to ensure the uninterrupted availability of essential inputs for pharmaceuticals and other manufacturing sectors.

Key Points: Pharma Raw Material Costs Rise, Govt Caps Medicine Prices

  • Petrochemical supply chain disruptions affect pharma
  • Raw material costs have increased
  • Government permission required for medicine price hikes
  • Customs duty exemption on key inputs until 2026
  • Move aims to stabilize supplies for multiple industries
2 min read

'Pharmaceuticals affected, but medicine prices won't rise without govt permission:' Jatish Sheth

Pharma industry faces rising costs due to West Asia conflict, but government permission is required for any medicine price increase. New duty exemptions announced.

"We do not increase the price of the medicines without the permission of the government. - Jatish Sheth"

Bengaluru, April 4

The ongoing conflict in West Asia is sending ripples through the pharmaceutical industry, with raw material costs on the rise, says Jatish Sheth, Director of Srushti Pharmaceuticals.

While speaking to ANI, Sheth highlighted that pharmaceuticals are vulnerable to disruptions in petrochemical supply chains, as many raw materials used in formulation are petrol-based.

"Pharmaceuticals are affected. Raw materials which are used for manufacturing formulation, they use petrol-based products... If the petrochemical supply is affected, the synthesis raw material will be affected, and in turn, medicines will be affected." Sheth explained. While the impact hasn't been severe so far, prolonged conflict could lead to shortages and increased costs.

"So far, it is not affecting badly, but if it goes on for long, it will get affected... Rates of input materials have gone up," Sheth noted, adding that the company is exercising caution on pricing.

"We do not increase the price of the medicines without the permission of the government. As far as pharmaceutical medicines are concerned, there won't be an increase in the price till the government gives the indication," he added.

Meanwhile, the Government on Wednesday announced a full customs duty exemption on select critical petrochemical products, in a move to cushion domestic industries from global supply disruptions due to the ongoing conflict in West Asia.

According to an official statement, the exemption will remain in force till June 30, 2026, and aims to ensure the uninterrupted availability of essential petrochemical inputs for domestic manufacturing sectors.

The decision comes amid heightened geopolitical tensions in West Asia, which have led to disruptions in global supply chains and increased cost pressures on industries reliant on petrochemical feedstock and intermediates.

The government said the measure is intended as a temporary relief to stabilise supplies, ease input costs, and support downstream industries that depend heavily on such raw materials.

A wide range of sectors is expected to benefit from the exemption, including plastics, packaging, textiles, pharmaceuticals, chemicals, automotive components, and other manufacturing segments. The move is also likely to provide indirect relief to consumers by moderating the prices of final products.

The list of exempted items includes key petrochemical inputs such as anhydrous ammonia, methanol, toluene, styrene, vinyl chloride monomer, monoethylene glycol (MEG), phenol, acetic acid, and purified terephthalic acid (PTA), among others.

- ANI

Share this article:

Reader Comments

R
Rohit P
Good to hear prices won't rise arbitrarily, but let's be real. If input costs keep climbing, companies will eventually pass it on, government permission or not. The duty exemption till 2026 is a smart move to buy time and stabilize supply chains. 🤞
A
Aman W
It's concerning how dependent our medicine supply is on global petrochemicals and conflicts in far-off regions. We really need to focus on 'Atmanirbhar Bharat' in pharma raw materials. This is a wake-up call for long-term strategic planning.
S
Sarah B
While the commitment to not raise prices without permission is commendable, I hope the government's approval process is swift and data-driven if a genuine need arises. Bureaucratic delays could ironically hurt supply if companies can't cover their costs at all.
K
Karthik V
The exemption list with MEG, PTA etc. shows the government has done its homework. This should prevent shortages. As a consumer, my bigger worry is availability, not just price. Hope the message reaches all local chemists so there's no panic buying.
M
Meera T
Thank you for the clear explanation. Many of us don't realize the link between petrol and our medicine. Articles like this are important for public awareness. The government's temporary relief measure seems sensible to navigate this global uncertainty.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50